Chandrabhan Seniya

Dr. Chandrabhan Seniya

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Biochemistry Research International
Verified
Journal Article
Open access
PDF file
CSChandrabhan Seniya
Chandrabhan Seniya
GKGhulam Jilani Khan
Ghulam Jilani Khan
KUKuldeep Uchadia
Kuldeep Uchadia
Cholinesterase inhibitors (ChE-Is) are the standard for the therapy of AD associated disorders and are the only class of approved drugs by the Food and Drug Administration (FDA). Additionally, acetylcholinesterase (AChE) is the target for many Alzheimer’s dementia drugs which block the function of AChE but have some side effects. Therefore, in this paper, an attempt was made to elucidate cholinesterase inhibition potential of secondary metabolite fromCannabisplant which has negligible or no side effect. Molecular docking of 500 herbal compounds, against AChE, was performed using Autodock 4.2 as per the standard protocols. Molecular dynamics simulations have also been carried out to check stability of binding complex in water for 1000 ps. Our molecular docking and simulation have predicted high binding affinity of secondary metabolite (C28H34N2O6) to AChE. Further, molecular dynamics simulations for 1000 ps suggest that ligand interaction with the residues Asp72, Tyr70-121-334, and Phe288 of AChE, all of which fall under active site/subsite or binding pocket, might be critical for the inhibitory activity of AChE. This approach might be helpful to understand the selectivity of the given drug molecule in the treatment of Alzheimer's disease. The study provides evidence for consideration ofC28H34N2O6as a valuable small ligand molecule in treatment and prevention of AD associated disorders and furtherin vitroandin vivoinvestigations may prove its therapeutic potential.

6 August 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
NSNand Kishore Sah
Nand Kishore Sah
CSChandrabhan Seniya
Chandrabhan Seniya

20 October 2010 in FEBS Letters
Verified
Journal Article
Closed access
ASAnitha Selvan
Anitha Selvan
CSChandrabhan Seniya
Chandrabhan Seniya
SCSrinivas Niranj Chandrasekaran
Srinivas Niranj Chandrasekaran
NSNithyanand Siddharth
Nithyanand Siddharth
SASharmila Anishetty
Sharmila Anishetty
GPGautam Pennathur
Gautam Pennathur

9 January 2013 in Bioinformation
Verified
Journal Article
Open access
CSChandrabhan Seniya
Chandrabhan Seniya
HMHarshal Mishra
Harshal Mishra
AYAjay Yadav
Ajay Yadav
NSNitin Sagar
Nitin Sagar
BCBabita Chaturvedi
Babita Chaturvedi
GWGulshan Wadhwa
Gulshan Wadhwa
4-hydroxypanduratin A is a secondary metabolite of Boesenbergia pandurata Schult. (Fingerroot) plant with various pharmacological activities such as neuroprotective, potent antioxidant, antibacterial and antifungal. Flaviviral NS2B/NS3 protease activity is essential for polyprotein processing and viral replication for Japanese Encephalitis Virus (JEV), a major cause of Acute Encephaltis in Asia. Inhibition of formation of this complex by arresting the binding of NS2B with NS3 would reduce the enzyme's activity to meager proportions and hence would prevent further viral proliferation. The automated 3D structure of NS2B protein of the JEV GP78 was predicted based on the sequence-to-structure-to-function paradigm using I-TASSER and the function of NS2B protein was inferred by matching to other known proteins. The stereochemical quality of predicted structure was checked by PROCHECK. The antiviral activity of 4-hydroxypanduratin A against NS2B protein as a potential drug has been elucidated in this paper. Docking simulation analysis showed 4-hydroxypanduratin A as potential inhibitor of NS2B protein/cofactor which is necessary for NS3 protease activity. 220 derivatives of 4-hydroxypanduratin A were virtually screened with rigid criteria of Lipinski's rule of 5 using Autodock4.2. 4-hydroxypanduratin A was found interacting with target hydrophilic domain in NS2B protein by two Hbonds (Gly80 and Asp81) with active residues, several hydrophobic interactions, Log P value of 5.6, inhibition constant (Ki) of 51.07nM and lowest binding energy of -9.95Kcal/Mol. Hence, 4-hydroxypanduratin A targeted to Site 2 will have sufficient profound effect to inhibit protease activity to abrogate viral replication. It could be a promising potential drug candidate for JEV infections using NS2B Site 2 as a Drug target.

1 September 2014 in Asian Pacific Journal of Tropical Disease
Verified
Journal Article
Closed access
CSChandrabhan Seniya
Chandrabhan Seniya
SSShilpi Shrivastava
Shilpi Shrivastava
SSSanjay Kumar Singh
Sanjay Kumar Singh
GKGhulam Jilani Khan
Ghulam Jilani Khan

11 January 2024 in Heliyon
Verified
Journal Article
Open access
SRSmita Rakshit
Smita Rakshit
AMAshwini More
Ashwini More
SGShraddha Gaikwad
Shraddha Gaikwad
CSChandrabhan Seniya
Chandrabhan Seniya
AGAniket K Gade
Aniket K Gade
KKKapil Kamble
Kapil Kamble
Diosgenin, an essential sapogenin steroid with significant biological implications, is composed of a hydrophilic sugar moiety intricately linked to a hydrophobic steroid aglycone. While the antiviral properties of diosgenin against numerous RNA viruses have been extensively documented, its potential in combating Human Immunodeficiency Virus infections remains unexplored. This current investigation presents a comprehensive and systematic analysis of extracts derived from the leaves of Helicteres isora, which are notably enriched with diosgenin. Rigorous methodologies, including established chromatographic techniques and Fourier-transform infrared spectroscopy were employed for the characterization of the active diosgenin compound followed by molecular interaction analyses with the key HIV enzymes and mechanistic validation of HIV inhibition. The inhibitory effects of extracted diosgenin on the replication of HIV-1 were demonstrated using a permissive cellular system, encompassing two distinct subtypes of HIV-1 strains. Computational analyses involving molecular interactions highlighted the substantial occupancy of critical active site pocket residues within the key HIV-1 proteins by diosgenin. Additionally, the mechanistic underpinnings of diosgenin activity in conjunction with standard controls were elucidated through specialized colorimetric assays, evaluating its impact on HIV-1 Reverse Transcriptase and Integrase enzymes. To our current state of knowledge, this study represents the inaugural demonstration of the anti-HIV efficacy inherent to diosgenin found in the leaves of Helicteres isora, and can be taken further for drug design and development for the management of HIV infection.